Oncolytic varicella-zoster virus engineered with ORF8 deletion and armed with drug-controllable interleukin-12
Background The varicella-zoster virus (VZV), belonging to the group of human α-herpesviruses, has yet to be developed as a platform for oncolytic virotherapy, despite indications from clinical case reports suggesting a potential association between VZV infection and cancer remission.Methods Here, we...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-03-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/12/3/e008307.full |